US86150R1077 - Common Stock
STOKE THERAPEUTICS INC
NASDAQ:STOK (5/8/2024, 7:20:33 PM)
After market: 11.6 0 (0%)11.6
-0.34 (-2.85%)
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 117 full-time employees. The company went IPO on 2019-06-19. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene.
STOKE THERAPEUTICS INC
45 Wiggins Avenue
Bedford MASSACHUSETTS 01730
P: 17814308200
CEO: Edward M. Kaye
Employees: 117
Website: https://www.stoketherapeutics.com/
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stoke Therapeutics (NASDAQ:STOK) just reported results for the first quarter of...
Here you can normally see the latest stock twits on STOK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: